Stereotactic Body Radiotherapy in the Treatment of Pancreatic Cancer

Seminars in Radiation Oncology

Volumn 24, Issue 2, 2014, Pages 140-147

  Trakul, Nicholas ^a   Koong, Albert C ^b   Chang, Daniel T ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; DOCETAXEL; FLUORODEOXYGLUCOSE; FLUOROURACIL; GEMCITABINE;

ADJUVANT CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURGERY; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; CYBERKNIFE; DIAGNOSTIC TEST ACCURACY STUDY; FATIGUE; HUMAN; INDUCTION CHEMOTHERAPY; INTENSITY MODULATED RADIATION THERAPY; LINEAR ACCELERATOR; MEDICAL TECHNOLOGY; MULTIDETECTOR COMPUTED TOMOGRAPHY; OVERALL SURVIVAL; PANCREAS CANCER; PANCREAS TUMOR; PHASE 2 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RADIATION DOSE DISTRIBUTION; RADIATION DOSE FRACTIONATION; RADIATION HAZARD; RADIATION SICKNESS; RADIOTHERAPY PLANNING SYSTEM; REVIEW; RISK ASSESSMENT; STEREOTACTIC BODY RADIATION THERAPY; STEREOTACTIC RADIOSURGERY; TUMOR VOLUME; VISUAL ANALOG SCALE; PANCREATIC NEOPLASMS; PROCEDURES; RADIOSURGERY; TREATMENT OUTCOME;

HUMANS; PANCREATIC NEOPLASMS; RADIOSURGERY; TREATMENT OUTCOME;

EID: 84895887050     PISSN: 10534296     EISSN: 15329461     Source Type: Journal    
DOI: 10.1016/j.semradonc.2013.11.008     Document Type: Review

References (53)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012, 62(1):10-29.
2. Vincent A., Herman J., Schulick R., et al. Pancreatic cancer. Lancet 2011, 378(9791):607-620.
3. Saif M.W. Pancreatic neoplasm in 2011: An update. J Pancreas 2011, 12(4):316-321.
4. Loehrer P.J., Feng Y., Cardenes H., et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: An Eastern Cooperative Oncology Group trial. J Clin Oncol 2011, 29(31):4105-4112.
5. Treatment of locally unresectable carcinoma of the pancreas: Comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. Gastrointestinal Tumor Study Group. J Natl Cancer Inst 1988, 80(10):751-755.
6. Willett C.G., Czito B.G., Bendell J.C., et al. Locally advanced pancreatic cancer. J Clin Oncol 2005, 23(20):4538-4544.
7. Iacobuzio-Donahue C.A., Fu B., Yachida S., et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol 2009, 27(11):1806-1813.
8. Paulson A.S., Tran Cao H.S., Tempero M.A., et al. Therapeutic advances in pancreatic cancer. Gastroenterology 2013, 144(6):1316-1326.
9. Trakul N., Koong A.C., Maxim P.G., et al. Modern radiation therapy techniques for pancreatic cancer. Gastroenterol Clin North Am 2012, 41(1):223-235.
10. Timmerman R., Paulus R., Galvin J., et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. J Am Med Assoc 2010, 303(11):1070-1076.
11. Lax I., Blomgren H., Naslund I., et al. Stereotactic radiotherapy of malignancies in the abdomen. Methodological aspects. Acta Oncol 1994, 33(6):677-683.
12. Chang B.K., Timmerman R.D. Stereotactic body radiation therapy: A comprehensive review. Am J Clin Oncol 2007, 30(6):637-644.
13. Xing L., Thorndyke B., Schreibmann E., et al. Overview of image-guided radiation therapy. Med Dosim 2006, 31(2):91-112.
14. 18F-FDG PET/CT for image-guided and intensity-modulated radiotherapy. J Nucl Med 2009, 50(10):1655-1665.
15. Rajagopalan M.S., Heron D.E. Role of PET/CT imaging in stereotactic body radiotherapy. Future Oncol 2010, 6(2):305-317.
16. 18Fluorodeoxyglucose PET is prognostic of progression-free and overall survival in locally advanced pancreas cancer treated with stereotactic radiotherapy. Int J Radiat Oncol Biol Phys 2010, 77(5):1420-1425.
17. Bussels B., Goethals L., Feron M., et al. Respiration-induced movement of the upper abdominal organs: A pitfall for the three-dimensional conformal radiation treatment of pancreatic cancer. Radiother Oncol 2003, 68(1):69-74.
18. Guckenberger M., Krieger T., Richter A., et al. Potential of image-guidance, gating and real-time tracking to improve accuracy in pulmonary stereotactic body radiotherapy. Radiother Oncol 2009, 91(3):288-295.
19. Wang X., Zhong R., Bai S., et al. Lung tumor reproducibility with active breath control (ABC) in image-guided radiotherapy based on cone-beam computed tomography with two registration methods. Radiother Oncol 2011, 99(2):148-154.
20. Ge J., Santanam L., Noel C., et al. Planning 4-dimensional computed tomography (4DCT) cannot adequately represent daily intrafractional motion of abdominal tumors. Int J Radiat Oncol Biol Phys 2013, 85(4):999-1005.
21. Jayachandran P., Minn A.Y., Van Dam J., et al. Interfractional uncertainty in the treatment of pancreatic cancer with radiation. Int J Radiat Oncol Biol Phys 2010, 76(2):603-607.
22. Park W.G., Yan B.M., Schellenberg D., et al. EUS-guided gold fiducial insertion for image-guided radiation therapy of pancreatic cancer: 50 successful cases without fluoroscopy. Gastrointest Endosc 2010, 71(3):513-518.
23. Kothary N., Dieterich S., Louie J.D., et al. Percutaneous implantation of fiducial markers for imaging-guided radiation therapy. Am J Roentgenol 2009, 192(4):1090-1096.
24. Chang S.D., Main W., Martin D.P., et al. An analysis of the accuracy of the CyberKnife: A robotic frameless stereotactic radiosurgical system. Neurosurgery 2003, 52(1):140-146. [discussion 146-147].
25. Scorsetti M., Alongi F., Castiglioni S., et al. Feasibility and early clinical assessment of flattening filter free (FFF) based stereotactic body radiotherapy (SBRT) treatments. Radiat Oncol 2011, 6:113.
26. Koong A.C., Le Q.T., Ho A., et al. Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2004, 58(4):1017-1021.
27. Koong A.C., Christofferson E., Le Q.T., et al. Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2005, 63(2):320-323.
28. Schellenberg D., Goodman K.A., Lee F., et al. Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2008, 72(3):678-686.
29. Schellenberg D., Kim J., Christman-Skieller C., et al. Single-fraction stereotactic body radiation therapy and sequential gemcitabine for the treatment of locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2011, 81(1):181-188.
30. Mahadevan A., Jain S., Goldstein M., et al. Stereotactic body radiotherapy and gemcitabine for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2010, 78(3):735-742.
31. Mahadevan A., Miksad R., Goldstein M., et al. Induction gemcitabine and stereotactic body radiotherapy for locally advanced nonmetastatic pancreas cancer. Int J Radiat Oncol Biol Phys 2011, 81(4):e615-e622.
32. Polistina F., Costantin G., Casamassima F., et al. Unresectable locally advanced pancreatic cancer: A multimodal treatment using neoadjuvant chemoradiotherapy (gemcitabine plus stereotactic radiosurgery) and subsequent surgical exploration. Ann Surg Oncol 2010, 17(8):2092-2101.
33. Gurka M.K., Collins S.P., Slack R., et al. Stereotactic body radiation therapy with concurrent full-dose gemcitabine for locally advanced pancreatic cancer: A pilot trial demonstrating safety. Radiat Oncol 2013, 8:44.
34. Hoyer M., Roed H., Sengelov L., et al. Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma. Radiother Oncol 2005, 76(1):48-53.
35. Didolkar M.S., Coleman C.W., Brenner M.J., et al. Image-guided stereotactic radiosurgery for locally advanced pancreatic adenocarcinoma results of first 85 patients. J Gastrointest Surg 2010, 14(10):1547-1559.
36. Rwigema J.C., Parikh S.D., Heron D.E., et al. Stereotactic body radiotherapy in the treatment of advanced adenocarcinoma of the pancreas. Am J Clin Oncol 2011, 34(1):63-69.
37. Goyal K., Einstein D., Ibarra R.A., et al. Stereotactic body radiation therapy for nonresectable tumors of the pancreas. J Surg Res 2012, 174(2):319-325.
38. Chuong M.D., Springett G.M., Freilich J.M., et al. Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated. Int J Radiat Oncol Biol Phys 2013, 86(3):516-522.
39. Trakul N., Harris J.P., Le Q.T., et al. Stereotactic ablative radiotherapy for reirradiation of locally recurrent lung tumors. J Thorac Oncol 2012, 7(9):1462-1465.
40. Lominska C.E., Unger K., Nasr N.M., et al. Stereotactic body radiation therapy for reirradiation of localized adenocarcinoma of the pancreas. Radiat Oncol 2012, 7:74.
41. Lagerwaard F.J., Haasbeek C.J.A., Smit E.F., et al. Outcomes of risk-adapted fractionated stereotactic radiotherapy for stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2008, 70(3):685-692.
42. Trakul N., Chang C.N., Harris J., et al. Tumor volume-adapted dosing in stereotactic ablative radiotherapy of lung tumors. Int J Radiat Oncol Biol Phys 2012, 84(1):231-237.
43. Onishi H., Araki T., Shirato H., et al. Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: Clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer 2004, 101(7):1623-1631.
44. Brown J.M., Diehn M., Loo B.W. Stereotactic ablative radiotherapy should be combined with a hypoxic cell radiosensitizer. Int J Radiat Oncol Biol Phys 2010, 78(2):323-327.
45. Murphy J.D., Christman-Skieller C., Kim J., et al. A dosimetric model of duodenal toxicity after stereotactic body radiotherapy for pancreatic cancer. Int J Radiat Oncol Biol Phys 2010, 78(5):1420-1426.
46. Bae S.H., Kim M.S., Cho C.K., et al. Predictor of severe gastroduodenal toxicity after stereotactic body radiotherapy for abdominopelvic malignancies. Int J Radiat Oncol Biol Phys 2012, 84(4):e469-e474.
47. Bae S.H., Kim M.S., Kim S.Y., et al. Severe intestinal toxicity after stereotactic ablative radiotherapy for abdominopelvic malignancies. Int J Colorectal Dis 2013.
48. Taniguchi C.M., Murphy J.D., Eclov N., et al. Dosimetric analysis of organs at risk during expiratory gating in stereotactic body radiation therapy for pancreatic cancer. Int J Radiat Oncol Biol Phys 2013, 85(4):1090-1095.
49. Murphy J.D., Chang D.T., Abelson J., et al. Cost-effectiveness of modern radiotherapy techniques in locally advanced pancreatic cancer. Cancer 2012, 118(4):1119-1129.
50. Bijlani A., Aguzzi G., Schaal D.W., et al. Stereotactic radiosurgery and stereotactic body radiation therapy cost-effectiveness results. Front Oncol 2013, 3:77.
51. ClinicalTrials.gov. Stereotactic body radiation therapy with or without gemcitabine hydrochloride in treating patients with pancreatic cancer that can be removed by surgery. http://clinicaltrials.gov/ct2/show.
52. Conroy T., Desseigne F., Ychou M., et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011, 364(19):1817-1825.
53. Hammel P., Huguet F., Van Laethem J., et al. Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with a locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or without erlotinib: Final results of the international phase III LAP 07 study. J Clin Oncol 2013, 31(suppl 15):LBA4003.